Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/2019-nCoV) poses a serious threat to global public health and local economies. As of March 3, 2020, over 80,000 cases have been confirmed in China, including 2946 deaths as well as over 10,566 confirmed cases in 72 other countries. Such huge numbers of infected and dead people call for an urgent demand of effective, available, and affordable drugs to control and diminish the epidemic.

Cited by papers we hold 42

• “The new normal”? Lessons from the treatment of emerging infectious diseases with old drugs · 2022
  Not checked
• Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19 · 2021
  No notice
• Potential Nanospray Inhalation of Remdesivir and Hydroxychloroquine using Poly (lactic-co-glycolic) Acid as Fast Delivery for Covid-19 Treatment. · 2021
  Not checked
• Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics · 2021
  Not checked
• Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy · 2021
  No notice
• An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come? · 2021
  Not checked
• A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study · 2021
  Not checked
• Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment · 2021
  No notice
• A call to caution when hydroxychloroquine is given to elderly patients with COVID-19 · 2021
  Not checked
• Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model · 2021
  Not checked
• COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus · 2021
  Not checked
• Therapeutic approaches against coronaviruses acute respiratory syndrome · 2021
  Not checked
• Impact of repurposed drugs on the symptomatic COVID-19 patients · 2021
  Not checked
• Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection · 2021
  No notice
• COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies · 2021
  No notice
• Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? · 2021
  No notice
• COVID-19: breaking down a global health crisis · 2021
  No notice
• Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 · 2021
  No notice
• COVID-19 Therapeutic Options Under Investigation · 2020
  Not checked
• In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication · 2020
  No notice

and 22 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.